Accentia settles investor suit for $1.35M; NIH awards Emergent, PharmAthene next-gen anthrax vax contracts;

> Accentia ($ABPI) has struck a $1.25 million deal to end an investor suit claiming that it lied to investors about the performance of an in-development non-Hodgkin's lymphoma treatment vaccine. Report (reg. req.)

> Emergent BioSolutions ($EBS) and PharmAthene ($PIP) have won contracts worth $28 million-plus each from the NIH to make next-generation anthrax vaccines. More | Release

> BiondVax has received a grant of 4.87 million NIS ($1.3 million) from Israel's Ministry of Economy to continue the clinical program for its universal influenza vaccine. More

> The U.S. has issued a patent for Soligenix's ($SGNX) ThermoVax technology. Release

And Finally... Researcher Jean-Marie Andrieu believes he has found a drinkable, probiotic-rich vaccine to ward off HIV. More

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan